The UK peptide therapeutics market will see a considerable growth of 3.7% during the forecast period. Well established healthcare infrastructure is also one of the key reasons which are expected to promote the acceptance of peptide therapeutics in the UK for the treatment of various health conditions, such as CVD, cancer, and others. The market players in the UK are focusing on the integration of novel technologies, to enhance the treatment of peptide therapeutics in the country.
Browse the full report description of "UK Peptide Therapeutics Market Size, Share & Trends Analysis Report, By Route of Administration (Oral and Parenteral), by Application (Cancer, Metabolic Disorder, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others), Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/uk-peptide-therapeutics-market
The significant prevalence of cancer and respiratory disorders in the UK has led the players to invest in the R&D of new technologies to promote the effective treatment of cancer across the country. For instance, in February 2020, Genentech in partnership with Bicycle Therapeutics entered a drug discovery in cancer research for the clinical-stage biotech. Bicycle Therapeutics is a Cambridge based company, developing a new class of drugs comprised of peptides, which are chains of amino acids. The partnership covers up to 4 drugs that are used to treat multiple immuno-oncology targets.
Market Coverage
Report Elements |
Details |
Study Period |
2019-2026 |
Base year |
2019 |
Forecast period |
2020-2026 |
Segments Covered |
By Route of Administration and By Application |
Key Companies Profiled |
Novo Nordisk A/S,
AstraZeneca Plc, GlaxoSmithKline PLC, Sanofi SA, and Novartis International
AG |
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID-19
o Most affected segment
o Recommendations
UK Peptide Therapeutics Market – Segmentation
By Route of Administration
By Application